Cancers,
Journal Year:
2024,
Volume and Issue:
16(4), P. 680 - 680
Published: Feb. 6, 2024
In
recent
years,
the
emergence
of
cancer
drug
resistance
has
been
one
crucial
tumor
hallmarks
that
are
supported
by
level
genetic
heterogeneity
and
complexities
at
cellular
levels.
Oxidative
stress,
immune
evasion,
metabolic
reprogramming,
overexpression
ABC
transporters,
stemness
among
several
key
contributing
molecular
response
mechanisms.
Topo-active
drugs,
e.g.,
doxorubicin
topotecan,
clinically
active
utilized
extensively
against
a
wide
variety
human
tumors
often
result
in
development
failure
to
therapy.
Thus,
there
is
an
urgent
need
for
incremental
comprehensive
understanding
mechanisms
specifically
context
topo-active
drugs.
This
review
delves
into
intricate
mechanistic
aspects
these
intracellular
extracellular
explores
use
potential
combinatorial
approaches
utilizing
various
drugs
inhibitors
pathways
involved
resistance.
We
believe
this
will
help
guide
basic
scientists,
pre-clinicians,
clinicians,
policymakers
toward
holistic
interdisciplinary
strategies
transcend
resistance,
renewing
optimism
ongoing
battle
cancer.
Journal of Hematology & Oncology,
Journal Year:
2020,
Volume and Issue:
13(1)
Published: Dec. 1, 2020
The
aberrant
Wnt/β-catenin
signaling
pathway
facilitates
cancer
stem
cell
renewal,
proliferation
and
differentiation,
thus
exerting
crucial
roles
in
tumorigenesis
therapy
response.
Accumulated
investigations
highlight
the
therapeutic
potential
of
agents
targeting
cancer.
Wnt
ligand/
receptor
interface,
β-catenin
destruction
complex
TCF/β-catenin
transcription
are
key
components
cascade
have
been
targeted
with
interventions
preclinical
clinical
evaluations.
This
scoping
review
aims
at
outlining
latest
progress
on
current
approaches
perspectives
various
types.
Better
understanding
updates
inhibitors,
antagonists
activators
rationalizes
innovative
strategies
for
personalized
treatment.
Further
warranted
to
confirm
precise
secure
achieve
optimal
use
benefits
malignant
diseases.
Journal of Hematology & Oncology,
Journal Year:
2020,
Volume and Issue:
13(1)
Published: Dec. 1, 2020
Abstract
Over
the
past
few
decades,
RNA
sequencing
has
significantly
progressed,
becoming
a
paramount
approach
for
transcriptome
profiling.
The
revolution
from
bulk
to
single-molecular,
single-cell
and
spatial
approaches
enabled
increasingly
accurate,
individual
cell
resolution
incorporated
with
information.
Cancer,
major
malignant
heterogeneous
lethal
disease,
remains
an
enormous
challenge
in
medical
research
clinical
treatment.
As
vital
tool,
been
utilized
many
aspects
of
cancer
therapy,
including
biomarker
discovery
characterization
heterogeneity
evolution,
drug
resistance,
immune
microenvironment
immunotherapy,
neoantigens
so
on.
In
this
review,
latest
studies
on
technology
their
applications
are
summarized,
future
challenges
opportunities
discussed.
Experimental Hematology and Oncology,
Journal Year:
2020,
Volume and Issue:
9(1)
Published: Nov. 24, 2020
Abstract
Cyclic
adenosine
monophosphate
(cAMP)
is
the
first
discovered
second
messenger,
which
plays
pivotal
roles
in
cell
signaling,
and
regulates
many
physiological
pathological
processes.
cAMP
can
regulate
transcription
of
various
target
genes,
mainly
through
protein
kinase
A
(PKA)
its
downstream
effectors
such
as
cAMP-responsive
element
binding
(CREB).
In
addition,
PKA
phosphorylate
kinases
Raf,
GSK3
FAK.
Aberrant
cAMP–PKA
signaling
involved
types
human
tumors.
Especially,
may
have
both
tumor-suppressive
tumor-promoting
depending
on
tumor
context.
cancer
growth,
migration,
invasion
metabolism.
This
review
highlights
important
cAMP–PKA–CREB
tumorigenesis.
The
potential
strategies
to
this
pathway
for
therapy
are
also
discussed.
Drug Resistance Updates,
Journal Year:
2021,
Volume and Issue:
59, P. 100796 - 100796
Published: Dec. 1, 2021
Driver
mutations
promote
initiation
and
progression
of
cancer.
Pharmacological
treatment
can
inhibit
the
action
mutant
protein;
however,
drug
resistance
almost
invariably
emerges.
Multiple
studies
revealed
that
cancer
is
based
upon
a
plethora
distinct
mechanisms.
Drug
occur
in
same
protein
or
different
proteins;
as
well
pathway
parallel
pathways,
bypassing
intercepted
signaling.
The
dilemma
clinical
oncologist
facing
not
all
genomic
alterations
tumor
microenvironment
facilitate
cell
proliferation
are
known,
neither
likely
to
metastasis.
For
example,
common
KRas
Cancer Discovery,
Journal Year:
2022,
Volume and Issue:
12(3), P. 606 - 624
Published: Jan. 4, 2022
Combination
therapies
are
superior
to
monotherapy
for
many
cancers.
This
advantage
was
historically
ascribed
the
ability
of
combinations
address
tumor
heterogeneity,
but
synergistic
interaction
is
now
a
common
explanation
as
well
design
criterion
new
combinations.
We
review
evidence
that
independent
drug
action,
described
in
1961,
explains
efficacy
practice-changing
combination
therapies:
it
provides
populations
patients
with
heterogeneous
sensitivities
multiple
chances
benefit
from
at
least
one
drug.
Understanding
response
heterogeneity
could
reveal
predictive
or
pharmacodynamic
biomarkers
more
precise
use
existing
drugs
and
realize
benefits
additivity
synergy.Significance:.
The
model
action
represents
an
effective
means
predict
magnitude
likely
be
observed
clinical
trials
therapies.
"bet-hedging"
strategy
implicit
suggests
individual
often
only
subset—sometimes
one—of
combination.
Personalized,
targeted
therapy,
consisting
agents
active
particular
patient,
will
increase,
perhaps
substantially,
therapeutic
benefit.
Precision
approaches
this
type
require
better
understanding
variability
biomarkers,
which
entail
preclinical
research
on
diverse
panels
cancer
models
rather
than
studying
synergy
unusually
sensitive
models.
Journal of Hematology & Oncology,
Journal Year:
2021,
Volume and Issue:
14(1)
Published: July 27, 2021
Abstract
N6-methyladenosine
(m6A)
has
emerged
as
an
abundant
modification
throughout
the
transcriptome
with
widespread
functions
in
protein-coding
and
noncoding
RNAs.
It
affects
fates
of
modified
RNAs,
including
their
stability,
splicing,
and/or
translation,
thus
plays
important
roles
posttranscriptional
regulation.
To
date,
m6A
methyltransferases
have
been
reported
to
execute
deposition
on
distinct
RNAs
by
own
or
forming
different
complexes
additional
partner
proteins.
In
this
review,
we
summarize
function
these
regulating
key
genes
pathways
cancer
biology.
We
also
highlight
progress
use
mediating
therapy
resistance,
chemotherapy,
targeted
therapy,
immunotherapy
radiotherapy.
Finally,
discuss
current
approaches
clinical
potential
methyltransferase-targeting
strategies.
Journal of Hematology & Oncology,
Journal Year:
2022,
Volume and Issue:
15(1)
Published: Oct. 8, 2022
Abstract
The
United
States
Food
and
Drug
Administration
(US
FDA)
has
always
been
a
forerunner
in
drug
evaluation
supervision.
Over
the
past
31
years,
1050
drugs
(excluding
vaccines,
cell-based
therapies,
gene
therapy
products)
have
approved
as
new
molecular
entities
(NMEs)
or
biologics
license
applications
(BLAs).
A
total
of
228
these
were
identified
cancer
therapeutics
cancer-related
drugs,
120
them
classified
therapeutic
for
solid
tumors
according
to
their
initial
indications.
These
evolved
from
small
molecules
with
broad-spectrum
antitumor
properties
early
stage
monoclonal
antibodies
(mAbs)
antibody‒drug
conjugates
(ADCs)
more
precise
targeting
effect
during
most
recent
decade.
extended
indications
other
malignancies,
constituting
treatment
system
monotherapy
combined
therapy.
However,
available
targets
are
still
mainly
limited
receptor
tyrosine
kinases
(RTKs),
restricting
development
drugs.
In
this
review,
summarized
indications,
characteristics,
functions.
Additionally,
RTK-targeted
therapies
immune
checkpoint-based
immunotherapies
also
discussed.
Our
analysis
existing
challenges
potential
opportunities
may
advance
tumor
future.
